Assessment of Portal Hypertension With Multiparametric MRI

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

69 participants

Study Classification

OBSERVATIONAL

Study Start Date

2018-03-20

Study Completion Date

2022-07-19

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to determine whether new multiparametric magnetic resonance imaging (MRI) methods (including diffusion-weighted MRI, dynamic contrast-enhanced MRI, MR elastography and phase-contrast imaging) can be useful in assessing liver damage and degree of portal hypertension (a complication of advanced liver fibrosis and cirrhosis) secondary to chronic liver disease, compared to ultrasound measurement of liver stiffness \[acoustic radiation force impulse (ARFI) ultrasound\] and routine blood tests. MRI uses magnetic fields to look at soft tissues in the body. This study will ultimately help to determine whether these methods will be useful in identifying liver disease and their complications that cannot be well-understood using current liver MRI techniques.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Multiparametric Cardio-hepatic MRI in Patients With Noncirrhotic Portal Hypertension

NCT05041452

Hypertension, Portal Cardiomyopathies

UNKNOWN

3D-MRE and 2D-MRE for Assessing Cirrhosis and Portal Hypertension

NCT06205992

Cirrhosis Liver Portal Hypertension

RECRUITING

Portal Hypertension Using Magnetic Resonance Elastography

NCT05749198

Portal Hypertension Magnetic Resonance Imaging

COMPLETED

Magnetic Resonance Imaging of Blood Flow in the Liver and Abdomen

NCT00001719

Healthy Liver Disease

COMPLETED

Cardiac MRI in Pulmonary Hypertension

NCT02485977

Pulmonary Hypertension

COMPLETED

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Liver cirrhosis has been historically classified as a single histopathologic entity, as it is considered to be the latest fibrosis stage; however it is well known that cirrhosis encompasses different degrees of clinical severity. Advanced liver fibrosis and cirrhosis are commonly associated with portal hypertension, which is due to increased hemodynamic resistance of the liver leading to an increase in portal venous pressure. Portal hypertension leads to the development of esophageal varices associated with a high risk of bleeding, ascites and renal dysfunction. The definite diagnosis of portal hypertension is based on the measurement hepatic venous pressure gradient (HVPG), which is an indirect measure of portal pressure. This technique is invasive and not widely available. Portal hypertension may also be associated with a decrease in portal venous flow/velocity due to a higher parenchymal resistance to flow, and an increase in hepatic arterial flow secondary to an arterial buffer response that can be measured with phase-contrast magnetic resonance imaging (MRI). According to the researcher's recent data, the increased vascular pressure observed in portal hypertension affects liver and spleen stiffness as well as other viscoelastic properties measured with advanced 3D MR elastography, which may potentially be used as biomarkers of portal hypertension.

In this proposal, the researchers would like to validate noninvasive imaging biomarkers based on a short multiparametric MRI protocol for the quantification of changes in viscoelastic properties and flow metrics in the liver and spleen in relation to portal hypertension. This protocol could potentially be integrated in routine clinical MRI exams, and could significantly reduce the cost of care by decreasing the need for HVPG measurement, upper gastrointestinal endoscopies, and could provide a novel risk stratification scoring system of liver disease and portal hypertension based on MRI. This will be a highly significant progression in patients with liver disease.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Portal Hypertension Clinically Significant Portal Hypertension

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Patients with Chronic Liver Disease

mpMRI

Intervention Type PROCEDURE

Multiparametric MRI

ARFI US

Intervention Type PROCEDURE

Acoustic radiation force impulse is a type of ultrasound elastography

Control Group

No interventions assigned to this group

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

mpMRI

Multiparametric MRI

Intervention Type PROCEDURE

ARFI US

Acoustic radiation force impulse is a type of ultrasound elastography

Intervention Type PROCEDURE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Chronic liver disease (including all etiologies of liver disease)
* 18 years of age and older
* Patient is able to give informed consent for this study
* Patients preferably (but not necessarily) underwent/will undergo:

1. Liver biopsy (percutaneous or transjugular or surgical) performed within 6 months, as part of routine clinical care and/or HVPG measurement as part of their clinical care (within 6 months) and/or clinically indicated upper gastrointestinal endoscopy.

and/or
2. Liver transplant or liver resection performed as part of routine clinical care and/or
3. Medical therapy for portal hypertension or TIPS placement as part of routine clinical care.

Control group

* Healthy volunteers without history of liver disease (will be used for the purpose of image optimization). These subjects will NOT undergo HVPG measurement.
* 18 years of age and older

Exclusion Criteria

* Age less than 18 years
* Unable or unwilling to give informed consent
* Contra-indications to MRI

1. Electrical implants such as cardiac pacemakers or perfusion pumps
2. Ferromagnetic implants such as aneurysm clips, surgical clips, prostheses artificial hearts, valves with steel parts, metal fragments, shrapnel, tattoos near the eye, or steel implants
3. Ferromagnetic objects such as jewelry or metal clips in clothing
4. Pregnant subjects
5. Pre-existing medical conditions including a likelihood of developing seizures or claustrophobic reactions.

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes